カテゴリ： GlobalData, ドイツ, 企業調査

MorphoSys AG (MOR)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：MorphoSys AG (MOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014378
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product include MOR208, MOR202, MOR103, MOR209/ES414, MOR106, and MOR107, among others. It drugs are used in the treatment of different types of cancer, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases. Morphosys offers Human Combinatorial Antibody Library (HuCAL), a recombinant antibody technology which allows generation of therapeutic and diagnostic antibodies. The company provides clinical trials for cancer and inflammatory disorders. It conducts research and development activities with pharmaceutical and biotechnology companies. Morphosys is headquartered in Munich, Germany.

MorphoSys AG (MOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Lanthio Pharma Raises US$6 Million In Series A Financing 13
Partnerships 14
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 21
Licensing Agreements 22
MorphoSys Enters Into Licensing Agreement With GSK For MOR103 22
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
MorphoSys Enters into Licensing Agreement with Merck Serono 25
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 26
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 27
MorphoSys Enters Into Licensing Agreement With Novozymes 28
MorphoSys Expands Licensing Agreement With Shionogi 29
Genedata Expands Licensing Agreement with MorphoSys 30
Equity Offering 31
MorphoSys Raises USD124.3 Million in Private Placement of Shares 31
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 33
Acquisition 35
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 35
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 36
MorphoSys AG – Key Competitors 38
MorphoSys AG – Key Employees 39
MorphoSys AG – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Nov 07, 2017: MorphoSys Announces Third Quarter 2017 Results 41
Aug 03, 2017: MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 43
May 03, 2017: MorphoSys Reports Solid First Quarter 2017 45
Nov 07, 2016: MorphoSys Reports Results for the First Nine Months of 2016 47
Aug 01, 2016: MorphoSys Reports Results for the First Six Months of 2016 49
May 03, 2016: MorphoSys Reports Results for the First Three Months of 2016 51
Mar 02, 2016: MorphoSys Reports Results for Fiscal Year 2015 53
Mar 02, 2016: MorphoSys is in a strong financial position and focuses on own pipeline 56
Corporate Communications 57
Oct 30, 2017: Dr. Markus Enzelberger Appointed MorphoSys’s Chief Scientific Officer 57
Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSyss Dutch Lanthipeptide Subsidiary 58
Product News 59
12/06/2016: MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016 59
11/03/2016: MorphoSys announces data on MOR202 at Upcoming American Society of Hematology Annual Meeting 2016 60
10/17/2016: MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference 61
09/19/2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys’s Dutch Lanthipeptide Subsidiary 62
09/06/2016: MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL 63
06/06/2016: MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma at ASCO 2016 65
05/18/2017: MorphoSys to Present Clinical Data on MOR-202 at Upcoming ASCO Annual Meeting 2017 66
Clinical Trials 67
Feb 21, 2017: MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 67
Aug 03, 2016: MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL 68
Jun 17, 2016: MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment 69
Jun 06, 2016: MorphoSys Presents Updated Clinical Data for MOR208 in Non-Hodgkins Lymphoma at ASCO 2016 71
Apr 06, 2016: MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma 72
Other Significant Developments 73
Sep 05, 2017: MorphoSys Presents Vision for Growth at its Capital Markets Day 73
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MorphoSys AG, Deals By Therapy Area, 2011 to YTD 2017 9
MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Lanthio Pharma Raises US$6 Million In Series A Financing 13
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 21
MorphoSys Enters Into Licensing Agreement With GSK For MOR103 22
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
MorphoSys Enters into Licensing Agreement with Merck Serono 25
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 26
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 27
MorphoSys Enters Into Licensing Agreement With Novozymes 28
MorphoSys Expands Licensing Agreement With Shionogi 29
Genedata Expands Licensing Agreement with MorphoSys 30
MorphoSys Raises USD124.3 Million in Private Placement of Shares 31
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 33
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 35
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 36
MorphoSys AG, Key Competitors 38
MorphoSys AG, Key Employees 39
MorphoSys AG, Subsidiaries 40

★海外企業調査レポート[MorphoSys AG (MOR)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Idaho Power Co：発電所・企業SWOT分析
    Idaho Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • McDermott International Inc (MDRIQ)：企業の財務・戦略的SWOT分析
    McDermott International Inc (MDRIQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Silence Therapeutics Plc (SLN)：企業の財務・戦略的SWOT分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company's pipeline products include SLN124, SLN500 and SLN360. Its SLN124 is developed for the treatment of cardiovascula …
  • Isagen SA ESP：企業の発電所・SWOT分析2018
    Isagen SA ESP - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Awilco LNG ASA (ALNG)：企業の財務・戦略的SWOT分析
    Summary Awilco LNG ASA (Awilco LNG) a subsidiary of Awilhelmsen AS is an oil and gas company that provides LNG transportation programs. The company owns and operates LNG vessels intended for international trading. It offers LNG value chain such as liquefaction, production, regasification, transporta …
  • Canon Medical Systems Corp：医療機器：M&Aディール及び事業提携情報
    Summary Canon Medical Systems Corp (Canon Medical Systems), formerly known as Toshiba Medical Systems Corp, a subsidiary of Canon Inc, is a provider of medical diagnostic systems and comprehensive medical solutions. The company’s product portfolio include computed tomography systems, magnetic resona …
  • Siegfried Holding AG (SFZN)-製薬・医療分野：企業M&A・提携分析
    Summary Siegfried Holding AG (Siegfried) is a custom manufacturing organization (CMO). The company is active in the primary and secondary production of drugs. It develops and manufactures active pharmaceutical ingredients (APIs) for the research-based pharmaceutical industry and corresponding interm …
  • CymaBay Therapeutics Inc (CBAY)：製薬・医療：M&Aディール及び事業提携情報
    Summary CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Arhalofenate, an oral small molecule intended for t …
  • SK Kaken Co Ltd (4628)：企業の財務・戦略的SWOT分析
    SK Kaken Co Ltd (4628) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • The Boston Consulting Group：企業の戦略的SWOT分析
    The Boston Consulting Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Bayerische Motoren Werke AG (BMW)：企業の財務・戦略的SWOT分析
    Bayerische Motoren Werke AG (BMW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Atea ASA (ATEA)：企業の財務・戦略的SWOT分析
    Atea ASA (ATEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • NanoPass Technologies Ltd：医療機器：M&Aディール及び事業提携情報
    Summary NanoPass Technologies Ltd (NanoPass) is a medical device company that develops and commercializes intradermal delivery solutions for vaccines and drugs. The company's product include MicronJet600 needle, a single use microneedles based device for intradermal delivery. Its micronjet microneed …
  • OrthoAccel Technologies Inc：医療機器：M&Aディール及び事業提携情報
    Summary OrthoAccel Technologies Inc (AcceleDent) is a medical device company that manufactures, develops, and markets orthodontic treatment and dental care products. The company’s products include acceledent aura is an accelerated tooth movement device designed for faster orthodontic treatment based …
  • Borders & Southern Petroleum plc (BOR)：企業の財務・戦略的SWOT分析
    Summary Borders & Southern Petroleum Plc (Borders & Southern Petroleum) is an oil and gas company that offers exploration and development of hydrocarbons. The company holds interests in three production licenses in the Falkland Islands located south-east of the Islands. Its production licenses provi …
  • Sempra Energy：企業の戦略・SWOT・財務分析
    Sempra Energy - Strategy, SWOT and Corporate Finance Report Summary Sempra Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sunshine Oilsands Ltd (2012)：石油・ガス：M&Aディール及び事業提携情報
    Summary Sunshine Oilsands Ltd (Sunshine Oilsands) is an oil and gas company that develops holdings of oil sands and PN&G leases. The company owns and controls oil sands leases. Its properties include Thickwood, West Ells, Muskwa, Harper, Legend Lake and Portage, among others. Sunshine Oilsands also …
  • Kudelski SA (KUD)：企業の財務・戦略的SWOT分析
    Kudelski SA (KUD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Emcure Pharmaceuticals Ltd：企業の戦略的SWOT分析
    Emcure Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Norfolk Southern Corporation：企業の戦略・SWOT・財務分析
    Norfolk Southern Corporation - Strategy, SWOT and Corporate Finance Report Summary Norfolk Southern Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆